Trial resultsH2 2027a window, not a day
Phase 3 topline data for osavampator in major depressive disorder
Neurocrine Biosciences expects to report results from its Phase 3 study of Osavampator (NBI-1065845) for Major depressive disorder (adjunctive) in the second half of 2027 (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary
DetailsClinical trial results · also called: readout / topline data
- Company
- Neurocrine Biosciences, Inc. NBIX
- Drug
- Osavampator (NBI-1065845)
- For
- Major depressive disorder (adjunctive)
- Stage
- Phase 3 · the last stage before a drug can be approved
- When
- H2 2027 · the company gave a window, not a day; the calendar never invents one
- Source note
- Q2 2026 earnings release guides Phase 3 MDD readouts in 2027; on the Aug 2026 earnings call management targeted second half of 2027 for Phase 3 topline data.
- Checked
- Checked by a person when it was added
Check the sourcesdon’t take our word for it
- Source: fool.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- NBIX headlines on this site
Neurocrine Biosciences, Inc.
2 upcoming · 1 past catalysts
More from NBIX